明年力争实现生娃基本“不花钱”；重庆通报患儿疑似被注射失效药：存在违规丨医药早参

Group 1: National Healthcare Policy - The National Healthcare Security Administration aims to achieve "no out-of-pocket" expenses for childbirth within the policy scope nationwide by 2026, contingent on the affordability of the healthcare fund [1] - All provinces are required to include suitable childbirth pain relief projects in the fund payment scope and improve the management of insurance payments for assisted reproductive technology projects [1] Group 2: Medical Quality and Safety - The Chongqing Health Commission reported that a preliminary investigation found violations in drug storage practices at a children's hospital, leading to potential disciplinary actions against the involved medical staff [2] - The commission will continue to investigate and enhance medical quality and safety supervision to prevent future violations in medical services [2] Group 3: Pharmaceutical Developments - Junshi Biosciences announced that its clinical trial application for the dual-specific antibody-drug conjugate JS212 for treating advanced solid tumors has been approved by the FDA, marking a significant advancement in drug development [3] - JS212 is expected to be effective against a broader range of tumors and may overcome resistance issues compared to single-target ADC drugs [3] Group 4: Strategic Acquisitions - Zhaoli Pharmaceutical plans to acquire a "multi-trace element injection asset group" from Tibet Future and its two wholly-owned subsidiaries for a total price of 356 million RMB, aimed at optimizing product structure and enhancing competitive strength [4] - The demand for multi-trace element injections is growing in both pediatric nutritional support and adult critical care nutrition sectors, making this acquisition strategically beneficial for Zhaoli Pharmaceutical [4] Group 5: Capital Increase - Shenzhou Cell plans to jointly increase capital by 3 billion RMB in its subsidiary Shenzhou Cell Engineering, with the company contributing 2.6 billion RMB and its controlling shareholder contributing 400 million RMB [5] - Following the capital increase, the registered capital of Shenzhou Cell Engineering will rise to 1.3 billion RMB, improving the subsidiary's financial structure and reducing operational and financial risks [5]